Article
Comparability for Gene Therapy — Designing the CMC Evidence Package for Changes
Every gene therapy program changes its manufacturing process. The question is not whether you will need a comparability exercise — it is whether you will have the analytical…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Comparability for Gene Therapy — Designing the CMC Evidence Package for Changes
Every gene therapy program changes its manufacturing process. The question is not whether you will need a comparability exercise — it is whether you will have the analytical…
Article
CRL CMC Deficiency Patterns — Complete Response Letter Analysis
In July 2025, FDA released 202 redacted Complete Response Letters covering approvals from 2020 through 2024 — followed by 89 more on September 4, 2025 — and the…
Article
Process Performance Qualification for GT Vectors — FDA PV 2011 in a GT Context
The FDA's 2011 Process Validation Guidance was written for the pharmaceutical industry. Applying it to a GT vector manufacturing process requires translation — and where that translation is…
Article
FDA Complete Response Letter — CMC Root Cause Analysis and Re-Submission Strategy
A Complete Response Letter with CMC deficiencies is not a list of things FDA wants you to add to your submission. It is a precisely worded document in…
Article
Writing the GT Quality Overall Summary — Module 2.3 for a Gene Therapy BLA
The Quality Overall Summary for a gene therapy product is the document CBER reviewers read first. It either demonstrates integrated CMC understanding or reveals the gaps before they…
Article
FDA Pre-Submission Meetings for Complex Drug Products — Maximizing CMC Value in 60-Minute Meetings
A sponsor who walks out of a pre-NDA FDA meeting with confirmed minutes stating that their proposed bispecific antibody potency specification is acceptable has converted 60 minutes into…
Article
Lentiviral Vector CMC — Module 3 Sections That Differentiate Strong from Clinical Hold
Lentiviral vectors integrate into the host genome. That single biological fact shapes every CMC expectation CBER has for your drug substance — from the design of your packaging…
Article
Type A, B, and C FDA Meetings — CMC Request Strategy and the Pre-Submission Intelligence Framework
FDA formal meetings are among the most consequential strategic decisions in drug development, and most CMC teams use them incorrectly. Not because they fail to request them —…
Article
Gene Therapy Stability — Designing a Program That Supports Your Shelf-Life Claim
A gene therapy stability program is not a stability program until it measures the right attributes at the right timepoints. Most early-stage GT stability programs measure the convenient…
Article
FDA Accelerated Approval and CMC — Post-Marketing Commitment Management for Complex Drugs
FDA's Accelerated Approval pathway has approved more than 250 drugs since 1992. The clinical story dominates the regulatory narrative. What almost never appears in that narrative is the…
Article
GT Drug Substance and Product Specifications — Building a Release Package for BLA
Every gene therapy lot that goes into a patient was released against a specification. Whether that specification can be defended at BLA — across all lots, all timepoints,…
Article
FDA Breakthrough Therapy Designation — CMC Strategy Under Accelerated Development Timelines
Breakthrough Therapy Designation does not accelerate FDA's CMC review standards. It accelerates the clinical program, compresses the development timeline, and brings the NDA filing date forward — often…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.